Today, we announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® (taurolidine and heparin) meets the criteria for a Transitional Drug Add-On Payment (TDAPA) in the anti-infective functional category, beginning on July 1, 2024. Learn more: https://lnkd.in/esrxYe3a
Congratulations, the most vulnerable patients will benefit from this benefit.
Congrats Steve. We update our EMR clients with this kind of information, (TDAPA,TPINES). This is good to know.
good news 👊
Congratulations
Great news for Comedix and patients!
Congratulations!
Congrats!!
Endocrinologist and Lipidologist at Arizona Community Physicians
6moWhat the short sellers are relying on is that the company will need another stock offering in the near future. That is pretty much the only way short Sellers can succeed in what they are doing. But can that happen? It can happen only if there are no contracts with the 2 big dialysis companies. It is extremely unlikely that the 2 big dialysis companies will not sign contracts in the next few weeks. There is 99% chance that the 2 big dialysis companies will sign contracts with CorMedix this month. They are going to make money so it does not make any sense that they will lose this opportunity. But apparently the market is not realizing this at this time. After all we are tiny company with little to no communication with investors on the wall street. Going to these monotonous conferences time and again has not helped much so far. What will help is announcement of contracts and then big revenue. That is going to happen very soon. If the stock price still stays low despite revenue, the company will have the option to buy back the shares. So even though this market does not work for the retail investors, yet short sellers are going to have an extremely bad day very soon!! We have a great CEO and he will make it happen!